Compare Moderna, Inc. (MRNA) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Clear Secure Inc — how do they compare? Moderna, Inc. trades at $224.78 (market cap $78.65B), while Clear Secure Inc trades at $43.44 (market cap $4.44B). The key difference: Moderna, Inc. is far larger — about 17.7× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.33% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Clear Secure Inc for 19 Days on average.
| MRNA | YOU | |
|---|---|---|
Market Cap | $78.65B | $4.44B |
Volume | 37,373,437 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $203.46 | $62.36 |
52-Week Low | $22.36 | $29.61 |
Typical Hold Time | 59 Days | 19 Days |
Enterprise Value | $74.80B | $3.59B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Clear Secure (YOU) trades at $43.55, up 2.28% today, with a bullish technical signal despite overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with $0.49 EPS, and shows robust revenue growth and profitability, including a 66.66% gross margin. Recent news highlights strategic partnerships, such as with CrowdStrike, and positive analyst coverage.
The outlook is positive, driven by accelerating membership growth and expanding margins, but risks include high valuation multiples and potential market volatility. Analysts have a consensus price target of $61.40, suggesting upside, with 44% buy ratings indicating cautious optimism amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
